PHARM — Pharming NV Cashflow Statement
0.000.00%
- €614.44m
- €625.81m
- $297.20m
- 90
- 14
- 44
- 46
Annual cashflow statement for Pharming NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 44.1 | 23.1 | 15 | -12 | -8.49 |
Depreciation | |||||
Non-Cash Items | 37.1 | 0.062 | -4.18 | -6.48 | 11.1 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -5.86 | -4.91 | -1.54 | -14.7 | -20.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 83.6 | 37.8 | 22.5 | -17.3 | -1.79 |
Capital Expenditures | -15.3 | -16.7 | -1.98 | -1.46 | -0.796 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.329 | -4.59 | 7.3 | -128 | 32.4 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Cash from Investing Activities | -15.6 | -21.3 | 5.32 | -129 | 31.6 |
Financing Cash Flow Items | -25.5 | -29.4 | -3.95 | -4.05 | -5.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 60.7 | -27.9 | -4.98 | -1.04 | -34.4 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 131 | -13.2 | 15.4 | -146 | -6.8 |